On March 6, 2023 Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy reported that it will present at the Supply Chain and Logistics for Cell Therapy Summit, March 7-9 in Boston, MA (Press release, Immunomic Therapeutics, MAR 6, 2023, View Source [SID1234628192]). Senior Director of External Manufacturing and Supply Chain, Shah Ahmed, will present a talk entitled, "Seamless Cell Therapy Supply: Addressing Bottlenecks, Building Contingencies & the Lessons Learned from Global Launches," at 4:55PM EDT on March 8, 2023.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details are as follows:
Presenter: Shah Ahmed
Title: Seamless Cell Therapy Supply: Addressing Bottlenecks, Building Contingencies & the Lessons Learned from Global Launches
Date and Time: Wednesday, March 8, 2023, 4:55PM EDT
Where: Hilton Boston Back Bay
About UNITE
ITI’s investigational UNITE platform, UNiversal Intracellular Targeted Expression, leverages the ability to engineer chimeric proteins, directing antigen presenting cells to present antigens to the immune system through a targeted pathway and driving a robust immune response. UNITE vaccines are distinct in that they combine two components: nucleic acid constructs that encode a specific antigen and an endogenous Lysosomal Associated Membrane Protein (LAMP-1) sequence. The UNITE platform harnesses LAMP-1 as a means of presenting the vaccine target to the immune system, resulting in antibody production, inflammatory cytokine release, and establishing critical immunological memory, something that other vaccine approaches commonly lack. This approach could put UNITE technology at the crossroads of immunotherapies in multiple indications, including cancer, human allergy, animal health, and infectious disease. Preclinical data is currently being developed to explore whether LAMP-1 nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and used to create immune responses in tumor types that otherwise do not provoke an immune response.